Our results raise the possibility that the decreased expression of apoptotic genes, BAX (0.4-fold) and CASP3 (0.5-fold), contributes to CLL cybrids’ resistance to ibrutinib treatment by increasing cell survival. The gene discussed is CASP3; the disease is B-cell chronic lymphocytic leukemia.